A loss of PARP results in an increase in the number of DNA damages repaired by homologous recombination, and thus PARP inhibitors are particularly efficacious in the tumor context of inhibited homologous recombination DNA repair mechanisms, such as BRCA mutations [20,21]. Here, PARP1 is linked to neoplasm.